Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
McKinsey
Boehringer Ingelheim
Federal Trade Commission
Accenture
Moodys
Deloitte
Fuji
Merck

Generated: February 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MITOMYCIN

« Back to Dashboard

Clinical Trials for Mitomycin

Trial ID Title Status Sponsor Phase Summary
NCT00002490 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed Medical Research Council Phase 3 RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not known whether receiving either radiation therapy, chemotherapy, or observation is more effective for cancer of the bladder. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy, chemotherapy, or observation following tumor surgery in treating patients who have bladder cancer.
NCT00002507 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed Yale University Phase 3 RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combining mitomycin or porfiromycin with radiation therapy is more effective in treating patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus either mitomycin or porfiromycin in treating patients with head and neck cancer.
NCT00002993 Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus Terminated National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin in treating patients with recurrent or advanced cancer of the uterus.
NCT00002993 Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus Terminated Gynecologic Oncology Group Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin in treating patients with recurrent or advanced cancer of the uterus.
NCT00003003 Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPOSE: Phase I trial to study the effectiveness of mitomycin and mitoxantrone in treating patients with acute myelogenous leukemia and to determine whether mitomycin can reduce the cancer's resistance to chemotherapy.
NCT00003003 Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia Completed Dartmouth-Hitchcock Medical Center Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPOSE: Phase I trial to study the effectiveness of mitomycin and mitoxantrone in treating patients with acute myelogenous leukemia and to determine whether mitomycin can reduce the cancer's resistance to chemotherapy.
NCT00003018 S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Mitomycin

Condition Name

Condition Name for Mitomycin
Intervention Trials
Bladder Cancer 21
Glaucoma 17
ColoRectal Cancer 8
Pancreatic Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mitomycin
Intervention Trials
Urinary Bladder Neoplasms 38
Carcinoma 31
Glaucoma 21
Neoplasm Metastasis 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mitomycin

Trials by Country

Trials by Country for Mitomycin
Location Trials
United States 310
United Kingdom 48
Italy 12
Korea, Republic of 11
Australia 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mitomycin
Location Trials
Texas 19
Pennsylvania 17
Maryland 16
California 16
New York 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mitomycin

Clinical Trial Phase

Clinical Trial Phase for Mitomycin
Clinical Trial Phase Trials
Phase 4 15
Phase 3 45
Phase 2/Phase 3 12
[disabled in preview] 107
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mitomycin
Clinical Trial Phase Trials
Completed 67
Recruiting 41
Unknown status 32
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mitomycin

Sponsor Name

Sponsor Name for Mitomycin
Sponsor Trials
National Cancer Institute (NCI) 30
European Organisation for Research and Treatment of Cancer - EORTC 5
Medical Research Council 5
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mitomycin
Sponsor Trials
Other 215
Industry 39
NIH 30
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Julphar
Fuji
Teva
QuintilesIMS
Accenture
Mallinckrodt
US Department of Justice
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.